Cadrenal Therapeutics director resigns; annual meeting set for September

Cadrenal Therapeutics , Inc. (NASDAQ:CVKD), a micro-cap biotech company with a market capitalization of $23.34 million, announced that Robert Lisicki has resigned from its board of directors, effective immediately, according to a statement filed with the Securities and Exchange Commission. InvestingPro data shows the company maintains a strong liquidity position with cash exceeding debt, though it faces challenges with rapid cash burn. The company noted that Lisicki’s decision to step down as a Class II Director was not due to any disagreement with Cadrenal Therapeutics regarding its operations, policies, or practices.

The filing also disclosed that Cadrenal Therapeutics plans to hold its 2025 annual meeting of stockholders on September 24, 2025, coming about a month after its next earnings report scheduled for August 7. The record date for shareholders entitled to vote at the meeting is set for the close of business on July 28, 2025. The announcement comes as the company’s stock has experienced an 8% decline over the past week, though it maintains an impressive 82% gain over the past year. Details regarding the time and location of the annual meeting will be provided in the company’s forthcoming proxy statement.

Due to the 2025 annual meeting being scheduled more than 30 days after the anniversary of the company’s 2024 annual meeting, previously disclosed deadlines for submitting shareholder proposals under SEC Rule 14a-8 are no longer applicable. The company has established July 28, 2025, as the new deadline for shareholders to submit proposals for inclusion in the proxy materials or to provide notice of director nominations and other proposals not intended for inclusion. This deadline also applies to shareholders who intend to solicit proxies in support of director nominees other than the company’s nominees, in accordance with SEC universal proxy rules.

Cadrenal Therapeutics stated that an adjournment or postponement of the annual meeting will not extend or begin a new period for submitting shareholder proposals or nominations.

The information in this article is based on a press release statement contained in the company’s recent SEC filing.

In other recent news, Cadrenal Therapeutics, Inc. has made notable advancements in the production of tecarfarin, its leading drug candidate for cardiovascular disease treatment. The company announced the completion of the technical transfer and production of the tecarfarin drug substance in compliance with current good manufacturing practices at a U.S. facility of a top global Contract Development and Manufacturing Organization. This development is crucial for Cadrenal’s clinical development strategy and aims to address unmet needs in anticoagulation therapy. Tecarfarin, a novel oral vitamin K antagonist, is designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring long-term anticoagulation therapy. The drug has received Orphan Drug designation for use in advanced heart failure patients with mechanical circulatory support devices and for end-stage kidney disease with atrial fibrillation. Additionally, it holds fast-track status for the latter indication. Cadrenal Therapeutics is also actively exploring business development opportunities as part of its long-term strategy to expand its pipeline of cardiovascular drugs.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.